Gt biopharma announces fda clearance of investigational new drug (ind) application for gtb-3650, an nk cell engager for treatment of cd33+ leukemia

San francisco, california, june 27, 2024 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced fda clearance of its ind application for gtb-3650, allowing the company to proceed with a phase 1 clinical trial, which is anticipated to start in second half of 2024.
GTBP Ratings Summary
GTBP Quant Ranking